Stachys schtschegleevii tea, matrix metalloproteinase, and disease severity in female rheumatoid arthritis patients: a randomized controlled clinical trial.
Elham MirtaheriAlireza KhabbaziHossein NazemiyehAli-Asghar EbrahimiMehrzad HajalilouZahra Shakibay NovinSaeed PirouzpanahPublished in: Clinical rheumatology (2021)
The SSC intervention showed an appropriate clinical efficacy for female RA patients, accompanying remarkable reductions in the number of tender and swollen joints, DAS28, and serum levels of MMP-3. This can provide additional insights to the interventional studies controlling RA-related pathological and inflammatory outcomes. Trial registration Prospectively registered at the Iranian Registry of Clinical Trials (IRCT), linked to the WHO Registry Network ( https://en.irct.ir/trial/11602 , IRCT registration number: IRCT2015032011335N5, Registration date:2015-05-12). Key Points • Stachys schtschegleevii improved clinical outcomes and attenuated disease severity in RA patients. • Stachys schtschegleevii ameliorated serum level of MMP-3 in RA patients.
Keyphrases
- end stage renal disease
- clinical trial
- newly diagnosed
- ejection fraction
- rheumatoid arthritis
- chronic kidney disease
- disease activity
- rheumatoid arthritis patients
- peritoneal dialysis
- prognostic factors
- oxidative stress
- systemic lupus erythematosus
- metabolic syndrome
- adipose tissue
- patient reported outcomes
- idiopathic pulmonary fibrosis
- interstitial lung disease
- patient reported
- weight loss